propranolol has been researched along with donepezil in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bienkowski, P; Bucki, A; Gobec, S; Godyń, J; Głuch-Lutwin, M; Kazek, G; Knez, D; Kołaczkowski, M; Malawska, B; Marcinkowska, M; Mierzejewski, P; Sienkiewicz-Jarosz, H; Siwek, A; Wichur, T; Więckowska, A; Więckowski, K; Zaręba, P | 1 |
| Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A; Podkowa, A; Sałat, K; Šink, R; Stojan, J; Trontelj, J; Žakelj, S; Živin, M | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Chen, JW; Chen, Y; Chen, YP; Geng, H; Li, Z; Luo, HB; Tian, YJ; Wang, Y; Wu, Y; Yu, YF; Zhang, C; Zhang, P; Zhang, T; Zhou, Q | 1 |
1 review(s) available for propranolol and donepezil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for propranolol and donepezil
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Humans; Indans; Indoles; Male; Memory; Mice; Models, Molecular; Neuroprotective Agents; Phthalimides; Piperidines; Protein Aggregates; Scopolamine; Structure-Activity Relationship | 2015 |
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Ligands; Male; Models, Molecular; Molecular Targeted Therapy; Protein Conformation; Rats; Rats, Wistar; Receptors, Serotonin | 2016 |
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
Topics: Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Crystallography, X-Ray; Drug Design; Female; Humans; Kinetics; Male; Mice; Models, Molecular; Protein Binding; Protein Conformation; Rats; Safety; Thermodynamics; Tissue Distribution | 2018 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Binding Sites; Catalytic Domain; Dementia, Vascular; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Maze Learning; Mice; Molecular Docking Simulation; Phosphodiesterase Inhibitors; Protein Isoforms; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2019 |